The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparing RECIST, Choi, modified Choi (mChoi) and viable tumor volume (VTV) in predicting clinical benefit of vascular endothelial growth factor receptor inhibitors (VEGFRi) in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC).
 
Michael Wotman
No Relationships to Disclose
 
Richard Dagher
No Relationships to Disclose
 
Camilla Hoff
Leadership - Oncologia D’Or (I)
Stock and Other Ownership Interests - Oncostar (I)
Honoraria - Bayer (I); Lilly (I)
Consulting or Advisory Role - Bayer (I); Lilly (I)
Research Funding - Exelixis (I); Lilly (I); Novartis (I)
 
Ahmed Msherghi
No Relationships to Disclose
 
Flavia Bonini
No Relationships to Disclose
 
Ethan Ludmir
Employment - Alaunos Therapeutics (I)
Honoraria - Nanobiotix
Consulting or Advisory Role - Xerient
 
Max Wintermark
Consulting or Advisory Role - Icometrix; Magnetic Insight; Subtle Medical
 
Renata Ferrarotto
Consulting or Advisory Role - Answers in CME; Bicara Therapeutics; Coherus Biosciences; Eisai; Labcorp Drug Development; Raptor Pharmaceuticals; Regeneron; Rgenta
Research Funding - Gilead Sciences (Inst); ISA Pharmaceuticals (Inst); Merck Serono (Inst); Pfizer/EMD Serono (Inst); Remix Therapeutics (Inst); Seagen (Inst); Viracta Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Royalties on UpToDate chapter on olfactory neuroblastoma, ~ 300 dollars per year
Travel, Accommodations, Expenses - Bicara Therapeutics